- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AstraZeneca PLC ADR (AZN)
Assess today's live AstraZeneca PLC ADR (AZN) share price, performance and insights using our live NASDAQ: AZN stock exchange data.
Analyse the historical data and AstraZeneca PLC ADR share price performance charts on this page. Our technical summary section provides analysis on AstraZeneca ADR share price buy/sell indicators using real-time data (or discuss the AstraZeneca ADR (AZN) stock price today with other investors in the AstraZeneca ADR NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ AZN share price (ISIN: US0463531089) to enhance your trading decisions with our free investment tools and resources.
What Is the AstraZeneca PLC ADR Share Price Today?
The AstraZeneca ADR share price today is 205.55.
What Is the Stock Symbol for AstraZeneca PLC ADR
The stock symbol (or 'ticker') for AstraZeneca PLC ADR is "AZN."
What Stock Exchange Does AstraZeneca PLC ADR Trade On?
AstraZeneca PLC ADR is listed and trades on the NASDAQ stock exchange.
Is AstraZeneca PLC ADR a Good Stock to Buy?
Determining whether AstraZeneca PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and AstraZeneca PLC ADR share price performance charts on this page. Our technical summary section provides analysis on AstraZeneca ADR share price buy/sell indicators using real-time data (or discuss the AstraZeneca ADR (AZN) stock price today with other investors in the AstraZeneca ADR NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ AZN share price (ISIN: US0463531089) to enhance your trading decisions with our free investment tools and resources.
What Is the AstraZeneca PLC ADR Share Price Today?
The AstraZeneca ADR share price today is 205.55.
What Is the Stock Symbol for AstraZeneca PLC ADR
The stock symbol (or 'ticker') for AstraZeneca PLC ADR is "AZN."
What Stock Exchange Does AstraZeneca PLC ADR Trade On?
AstraZeneca PLC ADR is listed and trades on the NASDAQ stock exchange.
Is AstraZeneca PLC ADR a Good Stock to Buy?
Determining whether AstraZeneca PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
204.09
206.71
52 wk Range
61.24
206.71
Trading near 52-week High
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
204.09206.71
52 wk Range
61.24206.71
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.65%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.65%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AZN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
135.50
Downside
-34.08%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
AstraZeneca ADR Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC ADR SWOT Analysis
Oncology Powerhouse | AstraZeneca's strong oncology portfolio drives growth, with flagship drugs like Imfinzi showing impressive revenue increases despite market challenges |
Pipeline Potential | Explore AstraZeneca's diverse pipeline, including promising treatments in hematologic malignancies and the highly anticipated AVANZAR trial results |
Strategic Growth | Delve into AstraZeneca's strategic acquisitions and partnerships, enhancing its portfolio and pipeline across multiple therapeutic areas |
Market Outlook | Analysts project positive growth, with price targets ranging from $85 to $89, reflecting confidence in AstraZeneca's financial health and market position |
AstraZeneca PLC ADR Earnings Call Summary for Q2/2025
- AstraZeneca's Q2 2025 EPS of $2.17 surpassed forecasts by 99.08%, with revenue reaching $14.46 billion, up 11% year-over-year
- Stock price rose 6.63% in pre-market trading following strong results, with the company on track for its $80 billion revenue target by 2030
- Double-digit growth across key markets, driven by oncology and biopharmaceuticals; R&D costs increased 17%, representing 23% of total revenue
- CEO Pascal Soriot emphasized long-term growth vision to 2030 and beyond, highlighting significant progress towards strategic ambitions
- Company forecasts high single-digit revenue growth and low double-digit EPS growth, with focus on oncology, obesity, and rare disease markets
Last Updated: 21/08/2025, 10:58
Read Full TranscriptCompare AZN to Peers and Sector
Metrics to compare | AZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.3x | 23.2x | −0.5x | |
PEG Ratio | 1.43 | 0.42 | 0.00 | |
Price/Book | 6.4x | 5.3x | 2.6x | |
Price / LTM Sales | 5.1x | 4.4x | 3.3x | |
Upside (Analyst Target) | −44.3% | −1.8% | 46.6% | |
Fair Value Upside | Unlock | 8.4% | 6.4% | Unlock |
Analyst Ratings
1 Buy
0 Hold
1 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 135.50
(-34.08% Downside)
Earnings
Latest Release
Feb 10, 2026
EPS / Forecast
2.12 / 1.06
Revenue / Forecast
15.50B / 15.48B
People Also Watch
FAQ
What Is the AstraZeneca ADR (AZN) Share Price Today?
The live AstraZeneca ADR share price today is 205.55
What Stock Exchange Does AstraZeneca ADR (AZN) Trade On?
AstraZeneca ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for AstraZeneca ADR?
The stock symbol (also called a 'ticker') for AstraZeneca ADR is "AZN."
Does AstraZeneca ADR Pay Dividends? What’s The Current AZN Dividend Yield?
Yes, AZN Pays Dividends to its Shareholders. The current AstraZeneca ADR dividend yield is 1.65%.
What Is the Current AstraZeneca ADR Market Cap?
As of today, AstraZeneca ADR market capitalisation is 320.10B.
What Is AstraZeneca ADR's (AZN) Earnings Per Share (TTM)?
The AstraZeneca ADR EPS is currently 6.60 (Trailing Twelve Months).
When Is the Next AstraZeneca ADR Earnings Date?
AstraZeneca ADR's next earnings report will be released on 29/04/2026.
Is AZN a Buy or Sell From a Technical Analyst Perspective?
Based on today's AstraZeneca ADR moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has AstraZeneca ADR Stock Split?
AstraZeneca ADR has split 2 times. (See the AZN stock split history page for full effective split date and price information.)
How Many Employees Does AstraZeneca ADR Have?
AstraZeneca ADR has 94300 employees.
What is the current trading status of AstraZeneca ADR (AZN)?
As of 14 Feb 2026, AstraZeneca ADR (AZN) is trading at a price of 205.55, with a previous close of 204.52. The stock has fluctuated within a day range of 204.09 to 206.71, while its 52-week range spans from 61.24 to 206.71.
What Is AstraZeneca ADR (AZN) Price Target According to Analysts?
The average 12-month price target for AstraZeneca ADR is USD135.50, with a high estimate of USD184 and a low estimate of USD87. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -34.08% Downside potential.
What Is the AZN Premarket Price?
AZN's last pre-market stock price is 204.93. The pre-market share volume is 30,790.00, and the stock has decreased by 0.41, or 0.20%.
What Is the AZN After Hours Price?
AZN's last after hours stock price is 206.25, the stock has decreased by 0.70, or 0.34%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.